Peripheral arterial disease in the elderly.
Wilbert S Aronow
https://pubmed.ncbi.nlm.nih.gov/18225466/Actively Recruiting
Led by Massachusetts General Hospital · Updated on 2026-09-11
484
Participants Needed
2
Research Sites
8 weeks
Total Duration
Researchers are evaluating a personalized blood clot prevention plan compared to standard treatment in adults with peripheral artery disease PAD who have undergone procedures to restore blood flow to their legs. This study aims to see if the personalized plan reduces blood clots, amputations, repeat procedures, bleeding, and death over one year. The personalized approach uses a blood test to tailor blood clot prevention medications. Participants are randomly assigned to either the personalized TARGET plan or standard treatment. The TARGET plan uses serial Thromboelastography with Platelet Mapping TEG-PM blood tests at 1 week and at 1, 3, 6, 9, and 12 months after the procedure to adjust antiplatelet medications and maintain platelet inhibition within a therapeutic range. The standard treatment group receives usual care with no medication changes based on TEG-PM results. Throughout the study, blood tests are collected regularly to monitor coagulation and platelet function. Researchers measure the incidence of arterial thrombosis in the treated limb and track rates of amputation-free survival, mortality, repeat interventions, and bleeding events up to 12 months after revascularization. Medication adjustments are made in the TARGET group based on test results, and all participants are followed for one year to assess outcomes and safety.
CONDITIONS
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
A
Anahita Dua, MBCHB, MBA, MSC
S
Swechha Bhatt, MBBS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Massachusetts General Hospital
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | TARGET personalized algorithm | Standard care (SOC arm) | Guideline‑recommended aspirin + low‑dose rivaroxaban |
|---|---|---|---|
| What it is | A personalized algorithm using TEG‑PM platelet mapping and VerifyNow P2Y12 resistance testing to guide escalation from clopidogrel to ticagrelor or initiation of rivaroxaban stepwise based on platelet function | A fixed postoperative antithrombotic regimen including dual antiplatelet therapy with clopidogrel plus aspirin or aspirin plus low‑dose rivaroxaban depending on surgeon preference | Low‑dose rivaroxaban (2.5 mg twice daily) combined with low‑dose aspirin is recommended in PAD patients post‑revascularization to reduce risk of cardiovascular and limb events |
| Role in trial | Investigational personalized treatment arm using platelet function‑guided escalation | Active comparator arm following fixed antiplatelet or antithrombotic regimen | Current guideline‑endorsed antithrombotic regimen but not part of this trial |
| Primary purpose | To reduce postoperative arterial thrombosis risk by tailoring therapy based on platelet function | To prevent thrombosis using established fixed antiplatelet or antithrombotic protocols | To reduce major adverse cardiovascular and limb events in revascularized PAD patients |
| How it is given or performed | Platelet function tests guide stepwise escalation from clopidogrel to ticagrelor or rivaroxaban based on resistance or insufficient inhibition thresholds | Fixed regimen of clopidogrel plus aspirin or aspirin plus low‑dose rivaroxaban as decided by surgeon | Low‑dose rivaroxaban given twice daily along with daily low‑dose aspirin |
| Evidence maturity | No published results yet; efficacy under prospective investigation | Clinical experience supports use but outcomes for this fixed regimen not established in this trial | Proven to reduce major adverse cardiovascular and limb events in PAD post‑revascularization |
| Important risks | Bleeding risk from antiplatelet and anticoagulant combinations; specific safety profile not yet published | Known bleeding risk from dual antiplatelet or aspirin‑rivaroxaban therapy | Increased bleeding risk must be considered when using low‑dose rivaroxaban plus aspirin |
| Limitations | Uncertain efficacy and safety until trial results are published; requires platelet function testing capability | Fixed regimen may not account for individual variability in platelet response | Requires assessment of bleeding risk; may not reflect all clinical contexts or patient subgroups |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 months
Participants receive postoperative antiplatelet therapy either through a personalized TARGET plan guided by blood tests or standard treatment. The TARGET group has medications adjusted to maintain platelet inhibition within a target range, while the standard group receives usual care without medication changes based on tests.
Visits and blood tests at 1 week, and 1, 3, 6, 9, and 12 months after the procedure
Duration - 12 months
Researchers monitor participants for arterial thrombosis, amputations, repeat procedures, bleeding events, and overall survival for up to 12 months post-procedure.
Regular assessments during treatment visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Wilbert S Aronow
https://pubmed.ncbi.nlm.nih.gov/18225466/Sasha Suarez, Aniket Agrawal, Shiv Patel...
https://pubmed.ncbi.nlm.nih.gov/38860382/Christopher D Owens, Karen J Ho, Michael S Conte
https://pubmed.ncbi.nlm.nih.gov/18372442/Monica Majumdar, Ryan P Hall, Zachary Feldman...
https://pubmed.ncbi.nlm.nih.gov/36565191/Connie N Hess, Lars Norgren, Gary M Ansel...
https://pubmed.ncbi.nlm.nih.gov/28630267/Sasha Suarez Ferreira, Aniket Agrawal, Ivy Lee...
https://pubmed.ncbi.nlm.nih.gov/39069123/Monica Majumdar, Davis Waller, Janelle Poyant...
https://pubmed.ncbi.nlm.nih.gov/36028157/Katie J Bates, Mykela M Moore, Morgane Cibotti-Sun
https://pubmed.ncbi.nlm.nih.gov/38752900/Ivy Lee, Sasha Suarez, Ryan Hall...
https://pubmed.ncbi.nlm.nih.gov/38441042/Massachusetts General Hospital
Lead Sponsor